ArticleJournal of gastroenterology2026
On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
backgroundLong-term nucleos(t)ide analog (NUC) treatment improves the outcomes of patients with chronic hepatitis B virus (HBV) infection. However, only a limited number of patients treated with NUC can achieve hepatitis B surface antigen (HBsAg) seroclearance, the so-called "functional cure." However, it remains unclear how on-treatment viral factors affect HBsAg seroclearance during long-term NUC treatment. We aimed to investigate whether the baseline and on-treatment HBV markers can predict HBsAg seroclearance and reduction in patients treated with long-term NUC treatment.
methodsThis study included two independent cohorts consisting of 843 patients in the derivation cohort and 1781 patients in the validation cohort.
resultsHBsAg seroclearance was infrequent (3.7-6.2%), with annual rates of 4-10/1,000 person-years in the derivation and validation cohorts. In baseline hepatitis B e-antigen (HBeAg)-positive patients, early on-treatment HBeAg loss strongly predicted subsequent HBsAg seroclearance and a reduction of < 10 IU/mL, whereas delayed or absent HBeAg loss rarely followed HBsAg seroclearance. A simple predictive model for HBsAg seroclearance based on earlier HBeAg loss, sex, and age was developed (SLOPES50). In baseline HBeAg-negative patients, low baseline or on-treatment HBsAg levels (< 100 IU/mL) were key predictors of HBsAg seroclearance or a reduction of < 10 IU/mL. Landmark analysis and time-dependent Cox regression analyses confirmed these associations in both cohorts. A substantial number of patients remained HBsAg ≥ 100 even after 15 years of NUC treatment in both cohorts.
conclusionsFunctional cure during prolonged NUC treatment of > 10 years depends on early virological responses in both HBeAg-positive and HBeAg-negative patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.